Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Cash & Equivalents: 2022-2025

Historic Cash & Equivalents for Orchestra BioMed Holdings (OBIO) over the last 4 years, with Sep 2025 value amounting to $74.0 million.

  • Orchestra BioMed Holdings' Cash & Equivalents rose 35.56% to $74.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $74.0 million, marking a year-over-year increase of 35.56%. This contributed to the annual value of $56.8 million for FY2024, which is 32.88% down from last year.
  • As of Q3 2025, Orchestra BioMed Holdings' Cash & Equivalents stood at $74.0 million, which was up 204.06% from $24.3 million recorded in Q2 2025.
  • Over the past 5 years, Orchestra BioMed Holdings' Cash & Equivalents peaked at $126.6 million during Q1 2023, and registered a low of $735,217 during Q3 2022.
  • In the last 3 years, Orchestra BioMed Holdings' Cash & Equivalents had a median value of $57.7 million in 2024 and averaged $71.9 million.
  • As far as peak fluctuations go, Orchestra BioMed Holdings' Cash & Equivalents surged by 13,962.51% in 2023, and later tumbled by 54.90% in 2025.
  • Orchestra BioMed Holdings' Cash & Equivalents (Quarterly) stood at $82.6 million in 2022, then climbed by 2.50% to $84.6 million in 2023, then slumped by 32.88% to $56.8 million in 2024, then surged by 35.56% to $74.0 million in 2025.
  • Its Cash & Equivalents was $74.0 million in Q3 2025, compared to $24.3 million in Q2 2025 and $40.2 million in Q1 2025.